Indian patent authority gives Pfizer monopoly on pneumonia medicine in India
The Indian patent authority has prolonged Pfizer’s monopoly on pneumonia medicine in India. The humanitarian health organization Médicines Sans Frontiéres (MSF) has appealed the decision to the Indian Supreme Court and pledges to continue the fight against expensive vaccines. It points out that the cost of fully vaccinating a child in accordance with the recommendations of the World Health Organization is 68 times more expensive than in 2001, and it places much of the blame on the practice of monopolizing vaccines. "The decision to grant patent to Pfizer is not only important in India – it has an effect on all middle and low income countries", said Øyunn Holen, medical director of MSF Norway.
News report – Bistandsaktuelt (in Norwegian)